HOUSTON, Feb. 29,
2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq:
FBLG) ("FibroBiologics") a clinical-stage biotechnology
company with 150+ patents issued and pending with a focus on the
development of therapeutics and potential cures for chronic
diseases using fibroblasts and fibroblast-derived materials has
filed its Annual Report on Form 10-K for the year ended
Dec. 31, 2023, with the U.S.
Securities and Exchange Commission.
The filing can be viewed through a link on FibroBiologics'
website at
https://ir.fibrobiologics.com/sec-filings/annual-reports. Upon
written request, stockholders may receive, free of charge, a paper
copy of FibroBiologics' Annual Report on Form 10-K (including
complete audited financial statements). Requests should be
communicated in writing to FibroBiologics, Attention: Investor
Relations, 455 E. Medical Center Blvd, Suite 300, Houston, TX 77598.
About FibroBiologics
Based in Houston, FibroBiologics
is a cell therapy, regenerative medicine company developing a
pipeline of treatments and potential cures for chronic diseases
using fibroblast cells and fibroblast-derived materials.
FibroBiologics holds 150+ US and internationally issued
patents/patents pending across various clinical pathways, including
disc degeneration, orthopedics, multiple sclerosis, psoriasis,
wound healing, reversing organ involution, and cancer.
FibroBiologics represents the next generation of medical
advancement in cell therapy. For more information, visit
www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic
Johnson or Harrison Seidner,
Ph.D.
Russo Partners
212-845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz
Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-files-2023-form-10-k-annual-report-302076516.html
SOURCE FibroBiologics